EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRTA, XNCR, ARVN, DRNA, FATE, and represent 36.63% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: FATE (+$41.99M), MRTX (+$22.51M), PBYI (+$21.40M), ANAB (+$15.12M), SGMO (+$14.70M), GMAB (+$13.86M), DNLI (+$12.22M), FOLD (+$11.55M), IONS (+$9.86M), MORF (+$9.81M).
- Started 21 new stock positions in FPRX, GMAB, SGMO, CRSP, FOLD, ZIOP, IONS, EXEL, VIR, MGTX. BMY.R, RGLS, VSTM, CRNX, BPMC, DNLI, TRIL, ZYME, PBYI, XOMA, LSACU.
- Reduced shares in these 10 stocks: FGEN (-$44.71M), ARGX (-$32.44M), , HARP (-$13.44M), SAGE (-$12.52M), ACAD (-$7.44M), EOLS (-$7.30M), KURA (-$7.27M), EIGR (-$6.70M), BCEL (-$6.21M).
- Sold out of its positions in ARGX, BMRN, EIGR, EOLS, HARP, IGMS, IOVA, RUBY, SAGE, TCRR. VCEL, XFOR, UROV.
- EcoR1 Capital was a net buyer of stock by $24.68M.
- EcoR1 Capital has $957.23M in assets under management (AUM), dropping by -13.72%.
Portfolio Holdings for EcoR1 Capital
Companies in the EcoR1 Capital portfolio as of the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| Prothena (PRTA) | 10.54 | 9.43M | 10.70 | |
| Xencor (XNCR) | 7.81 | 2.50M | 29.88 | |
| Arvinas Ord (ARVN) | 6.43 | 1.53M | +14% | 40.30 |
| Dicerna Pharmaceuticals (DRNA) | 6.42 | 3.35M | -7% | 18.37 |
| Fate Therapeutics (FATE) | 5.43 | 2.34M | +418% | 22.21 |
| Ironwood Pharmaceuticals (IRWD) | 4.63 | 4.39M | 10.09 | |
| Anaptysbio Inc Common (ANAB) | 4.48 | 3.04M | +54% | 14.13 |
| Neoleukin Therapeutics (NLTX) | 4.39 | 3.69M | -5% | 11.38 |
| Morphic Hldg (MORF) | 4.33 | 2.82M | +31% | 14.68 |
| Assembly Biosciences (ASMB) | 4.01 | 2.59M | +8% | 14.83 |
| Kura Oncology (KURA) | 3.65 | 3.51M | -17% | 9.95 |
| Fibrogen (FGEN) | 3.20 | 882.14k | -59% | 34.75 |
| Innate Pharma (IPHA) | 3.12 | 4.47M | 6.68 | |
| Mirati Therapeutics (MRTX) | 2.87 | 357.85k | +450% | 76.87 |
| Prevail Therapeutics Ord (PRVL) | 2.86 | 2.25M | 12.19 | |
| Puma Biotechnology (PBYI) | 2.24 | 2.54M | NEW | 8.44 |
| Merus N V (MRUS) | 2.17 | 1.72M | 12.10 | |
| Atreca Inc Cl A (BCEL) | 1.91 | 1.11M | -25% | 16.55 |
| Ultragenyx Pharmaceutical (RARE) | 1.72 | 371.21k | +41% | 44.43 |
| Sangamo Biosciences (SGMO) | 1.54 | 2.31M | NEW | 6.37 |
| Genmab A/s -sp (GMAB) | 1.45 | 653.98k | NEW | 21.19 |
| ACADIA Pharmaceuticals (ACAD) | 1.43 | 323.89k | -35% | 42.25 |
| Denali Therapeutics (DNLI) | 1.28 | 698.10k | NEW | 17.51 |
| Amicus Therapeutics (FOLD) | 1.21 | 1.25M | NEW | 9.24 |
| Selecta Biosciences (SELB) | 1.16 | 4.60M | 2.41 | |
| Ionis Pharmaceuticals (IONS) | 1.03 | 208.61k | NEW | 47.28 |
| Vir Biotechnology (VIR) | 0.97 | 270.42k | NEW | 34.27 |
| ZIOPHARM Oncology (ZIOP) | 0.96 | 3.75M | NEW | 2.45 |
| Verastem (VSTM) | 0.90 | 3.26M | NEW | 2.64 |
| Rts/bristol-myers Squibb Compa (BMY.R) | 0.89 | 2.25M | NEW | 3.80 |
| Cyclerion Therapeutics (CYCN) | 0.76 | 2.74M | +51% | 2.65 |
| Chiasma (CHMA) | 0.58 | 1.51M | -50% | 3.65 |
| Crinetics Pharmaceuticals In (CRNX) | 0.54 | 350.00k | NEW | 14.70 |
| Exicure (XCUR) | 0.44 | 2.84M | -19% | 1.48 |
| Arcus Biosciences Incorporated (RCUS) | 0.42 | 292.10k | -59% | 13.88 |
| Savara (SVRA) | 0.32 | 1.43M | 2.12 | |
| Lifesci Acquisition Corp unit 03/31/2025 (LSACU) | 0.31 | 300.00k | NEW | 10.00 |
| Surface Oncology (SURF) | 0.25 | 1.27M | -2% | 1.87 |
| Aclaris Therapeutics (ACRS) | 0.23 | 2.09M | 1.04 | |
| Corvus Pharmaceuticals (CRVS) | 0.16 | 737.61k | 2.11 | |
| Zymeworks (ZYME) | 0.15 | 41.41k | NEW | 35.48 |
| Crispr Therapeutics (CRSP) | 0.14 | 30.51k | NEW | 42.41 |
| Meiragtx Holdings (MGTX) | 0.13 | 94.82k | NEW | 13.44 |
| Trillium Therapeutics, Inc. Cmn (TRIL) | 0.12 | 292.00k | NEW | 4.04 |
| Xoma Corp Del (XOMA) | 0.11 | 50.81k | NEW | 20.35 |
| Regulus Therapeutics (RGLS) | 0.09 | 1.89M | NEW | 0.46 |
| Blueprint Medicines (BPMC) | 0.09 | 13.95k | NEW | 58.51 |
| Pieris Pharmaceuticals (PIRS) | 0.06 | 264.17k | -89% | 2.28 |
| Five Prime Therapeutics (FPRX) | 0.06 | 256.07k | NEW | 2.27 |
| Exelixis (EXEL) | 0.01 | 6.27k | NEW | 17.23 |
| Cytomx Therapeutics (CTMX) | 0.00 | 1.10k | -99% | 7.27 |
Download CSV 
Past Filings by EcoR1 Capital
View past SEC 13F filings by EcoR1 Capital
- EcoR1 Capital 2019 Q4 amended filed Feb. 18, 2020
- EcoR1 Capital 2019 Q4 filed Feb. 14, 2020
- EcoR1 Capital 2019 Q3 filed Nov. 14, 2019
- EcoR1 Capital 2019 Q2 filed Aug. 14, 2019
- EcoR1 Capital 2019 Q1 filed May 15, 2019
- EcoR1 Capital 2018 Q4 filed Feb. 14, 2019
- EcoR1 Capital 2018 Q3 filed Nov. 14, 2018
- EcoR1 Capital 2018 Q2 filed Aug. 14, 2018
- EcoR1 Capital 2018 Q1 filed May 15, 2018
- EcoR1 Capital 2017 Q4 filed Feb. 14, 2018
- EcoR1 Capital 2017 Q3 filed Nov. 14, 2017
- EcoR1 Capital 2017 Q2 filed Aug. 14, 2017
- EcoR1 Capital 2017 Q1 amended filed May 19, 2017
- EcoR1 Capital 2017 Q1 filed May 15, 2017
- EcoR1 Capital 2016 Q4 amended filed Feb. 15, 2017
- EcoR1 Capital 2016 Q4 amended filed Feb. 15, 2017
- EcoR1 Capital 2016 Q4 filed Feb. 14, 2017
- EcoR1 Capital 2016 Q3 filed Nov. 14, 2016
- EcoR1 Capital 2016 Q2 filed Aug. 15, 2016